Unlocking New Horizons: The Game-Changing Impact of a Single Nitrogen Atom on Drug Discovery

Scientists from the University of Oklahoma have established a groundbreaking technique for incorporating a single nitrogen atom into molecules, unveiling new avenues in pharmaceutical research and advancement. Recently published in the journal Science, this study is attracting international interest from pharmaceutical entities.

Nitrogen atoms and nitrogen-based chemical frameworks, known as heterocycles, are essential in medicinal chemistry and drug innovation. A team spearheaded by OU associate professor Indrajeet Sharma has shown that by utilizing a transient chemical called sulfenylnitrene, scientists can insert a nitrogen atom into bioactive compounds, modifying them into novel pharmacophores that are beneficial for drug creation.

This technique, referred to as skeletal editing, draws inspiration from Sir Derek Barton, who was awarded the Nobel Prize in Chemistry in 1969.

“Eighty-five percent of all drugs approved by the FDA contain one or more nitrogen atoms. Furthermore, when examining the top 200 brand-name pharmaceuticals, 75-80% incorporate nitrogen heterocycles,” he stated.

“By selectively integrating one nitrogen atom into these existing drug heterocycles during the later phases of development, we can alter the biological and pharmacological characteristics of the molecule without modifying its functionalities. This could unveil unexplored territories in drug discovery.”

Sharma noted that this skeletal editing approach fosters increased drug diversity because, instead of creating new pharmaceuticals from the ground up, researchers can insert a single nitrogen atom to develop a new array of drugs. Nitrogen is crucial in this process as DNA, RNA, proteins, and amino acids all comprise nitrogen, indicating that Sharma’s findings could have extensive implications on the potential treatment of ailments like cancer and neurological disorders.

Previous studies in this domain illustrated a similar principle but relied on traditional nitrenes and produced an excess of oxidizing agents, which were incompatible with numerous drug compounds. Sharma’s team implements a method to generate sulfenylnitrenes that is free of additives and metals and is compatible with other functional groups contained within the molecule.

“The expense associated with many drugs is linked to the number of steps involved in their production, and pharmaceutical companies seek methods to minimize these steps. By adding a nitrogen atom in the final stages of development, new drugs can be produced at a lower cost. It’s akin to refurbishing a structure rather than constructing it anew,” he remarked.

“Health care access is not uniform across the board. Even in the United States, annual health expenditures exceed $12,000 per person. By simplifying the large-scale production of these pharmaceuticals, we could lower health care costs for vulnerable populations globally.”